Documento de consenso de asma grave. Actualización 2025

Q4 Medicine
Francisco Javier Álvarez-Gutiérrez , Marina Blanco Aparicio , Francisco Casas Maldonado , Vicente Plaza , Gregorio Soto Campos , Francisco Javier González-Barcala , Carlos Almonacid , Ebymar Arismendi , Carlos Cabrera , Roberto Cabestre García , José Ángel Carretero , Manuel Castilla Martínez , José Antonio Castillo Vizuete , Carolina Cisneros Serrano , Álvaro Gimeno Díaz de Atauri , David Diaz Pérez , Christian Domingo Ribas , Juan Luis García Rivero , Alejandro López Neyra , Eva Martínez Moragón , José Valverde Molina
{"title":"Documento de consenso de asma grave. Actualización 2025","authors":"Francisco Javier Álvarez-Gutiérrez ,&nbsp;Marina Blanco Aparicio ,&nbsp;Francisco Casas Maldonado ,&nbsp;Vicente Plaza ,&nbsp;Gregorio Soto Campos ,&nbsp;Francisco Javier González-Barcala ,&nbsp;Carlos Almonacid ,&nbsp;Ebymar Arismendi ,&nbsp;Carlos Cabrera ,&nbsp;Roberto Cabestre García ,&nbsp;José Ángel Carretero ,&nbsp;Manuel Castilla Martínez ,&nbsp;José Antonio Castillo Vizuete ,&nbsp;Carolina Cisneros Serrano ,&nbsp;Álvaro Gimeno Díaz de Atauri ,&nbsp;David Diaz Pérez ,&nbsp;Christian Domingo Ribas ,&nbsp;Juan Luis García Rivero ,&nbsp;Alejandro López Neyra ,&nbsp;Eva Martínez Moragón ,&nbsp;José Valverde Molina","doi":"10.1016/j.opresp.2025.100486","DOIUrl":null,"url":null,"abstract":"<div><div>Severe asthma is a heterogeneous syndrome with several clinical variants and often represents a complex disease requiring a specialized and multidisciplinary approach, as well as the use of multiple drugs. The prevalence of severe asthma varies from one country to another, and it is estimated that 50% of these patients present a poor control of their disease. For the best management of the patient, it is necessary to have a correct diagnosis, an adequate follow-up and undoubtedly to offer the best available treatment, including biologic treatments with monoclonal antibodies. With this objective, this consensus process was born, which began in its first version in 2018, whose goal is to offer the patient the best possible management of their disease to minimize their symptomatology. For this 2025 consensus update, a literature review was conducted by the authors, and new sections of how to treat asthma comorbidities or pediatric asthma were added, as a paragraph about monoclonal antibody switch. Subsequently, through a two-round interactive Delphi process, a broad panel of asthma experts from SEPAR and the regional pulmonology societies proposed the recommendations and conclusions contained in this document.</div></div>","PeriodicalId":34317,"journal":{"name":"Open Respiratory Archives","volume":"7 4","pages":"Article 100486"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Respiratory Archives","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2659663625000906","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Severe asthma is a heterogeneous syndrome with several clinical variants and often represents a complex disease requiring a specialized and multidisciplinary approach, as well as the use of multiple drugs. The prevalence of severe asthma varies from one country to another, and it is estimated that 50% of these patients present a poor control of their disease. For the best management of the patient, it is necessary to have a correct diagnosis, an adequate follow-up and undoubtedly to offer the best available treatment, including biologic treatments with monoclonal antibodies. With this objective, this consensus process was born, which began in its first version in 2018, whose goal is to offer the patient the best possible management of their disease to minimize their symptomatology. For this 2025 consensus update, a literature review was conducted by the authors, and new sections of how to treat asthma comorbidities or pediatric asthma were added, as a paragraph about monoclonal antibody switch. Subsequently, through a two-round interactive Delphi process, a broad panel of asthma experts from SEPAR and the regional pulmonology societies proposed the recommendations and conclusions contained in this document.
严重哮喘的共识文件。2025年更新
严重哮喘是一种具有多种临床变异的异质性综合征,通常是一种复杂的疾病,需要专门和多学科的方法,以及使用多种药物。严重哮喘的患病率因国家而异,据估计,其中50%的患者病情控制不佳。为了对患者进行最佳治疗,必须有正确的诊断,充分的随访,并提供最好的治疗,包括单克隆抗体的生物治疗。有了这个目标,这个共识过程诞生了,它在2018年的第一个版本开始,其目标是为患者提供最好的疾病管理,以尽量减少他们的症状。对于此次2025共识更新,作者进行了文献综述,并增加了如何治疗哮喘合并症或儿科哮喘的新章节,作为关于单克隆抗体转换的段落。随后,通过两轮互动德尔菲程序,来自SEPAR和区域肺脏学会的广泛哮喘专家小组提出了本文件中包含的建议和结论。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Open Respiratory Archives
Open Respiratory Archives Medicine-Pulmonary and Respiratory Medicine
CiteScore
1.10
自引率
0.00%
发文量
58
审稿时长
51 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信